Revance Therapeutics Inc (NAS:RVNC)
$ 3.04 -0.02 (-0.65%) Market Cap: 317.35 Mil Enterprise Value: 618.80 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 67/100

Revance Therapeutics Inc at JPMorgan Healthcare Conference (Virtual) Transcript

Jan 14, 2021 / 08:40PM GMT
Release Date Price: $28.84 (-0.45%)
Unidentified Analyst

Hello, everyone. I'm Nater Surabhi from the JPMorgan Healthcare Investment Banking team. On behalf of JPMorgan, it's my pleasure to introduce Mark Foley, Chief Executive Officer of Revance. As a reminder, we will try to reserve a few minutes at the end for Q&A. So if you have any questions, please submit them online using the ask a question feature at the bottom of the screen.

I will now turn it over to Mark. Thank you.

Mark J. Foley
Revance Therapeutics, Inc. - President, CEO & Director

Great. Thanks, Nater, and thanks to the entire JPMorgan Healthcare team for having us as part of the conference. Look forward to giving you a company update here today.

You'll be able to click through the slides on your end, so I'll do my best to reference the different slides so that you can follow along. So moving from Slide 1 to Slide 2, this is our forward-looking statement as there will be different comments that we've been making about potential forward-looking results, which may end up differing.

Moving on to Slide 3,

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot